Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
ARS
2023 FY
Annual report to shareholders
9 Apr 24
S-8
Registration of securities for employees
4 Mar 24
S-3
Shelf registration
4 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
8-K
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
4 Mar 24
8-K
Other Events
29 Feb 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
In the Court of Chancery of the State of Delaware
29 Dec 23
8-K
Passage Bio Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 In FTD-GRN and Updated Strategic Priorities
20 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
13 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Sep 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7 Aug 23
8-K
Departure of Directors or Certain Officers
31 Jul 23
8-K
Departure of Directors or Certain Officers
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
11 May 23
ARS
2022 FY
Annual report to shareholders
14 Apr 23
DEFA14A
Additional proxy soliciting materials
14 Apr 23
DEF 14A
Definitive proxy
14 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
6 Mar 23
10-K
2022 FY
Annual report
6 Mar 23
8-K
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
6 Mar 23
8-K
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposiumâ„¢ 2023
24 Feb 23
8-K
Results of Operations and Financial Condition
9 Jan 23
8-K
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
14 Dec 22
8-K
Amendments to Articles of Incorporation or Bylaws
2 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
10 Nov 22
8-K
Departure of Directors or Certain Officers
11 Oct 22
8-K
Other Events
11 Aug 22
8-K
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
4 Aug 22
Latest ownership filings
SC 13D/A
ORBIMED ADVISORS LLC
12 Apr 24
SC 13G
Lynx1 Capital Management LP
29 Mar 24
4
Kathleen Borthwick
19 Mar 24
4
Mark S Forman
19 Mar 24
4
William Chou
19 Mar 24
4
Edgar B. Cale
19 Mar 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
4
Kathleen Borthwick
13 Feb 24
4
Mark S Forman
13 Feb 24
4
Mark S Forman
3 Jan 24
4
Kathleen Borthwick
3 Jan 24
4
Edgar B. Cale
3 Jan 24
SC 13D/A
Versant Venture Capital VI, L.P.
9 Nov 23
4
Simona King
1 Aug 23
4
Dolan Sondhi
31 Jul 23
3
Dolan Sondhi
31 Jul 23
4
Kathleen Borthwick
28 Jul 23
3
Kathleen Borthwick
28 Jul 23
4
Change in insider ownership
29 Jun 23
SC 13D/A
ORBIMED ADVISORS LLC
29 Jun 23
4
Alexandros Fotopoulos
20 Jun 23
SC 13D/A
Frazier Life Sciences IX, L.P.
15 Jun 23
4
Thomas Woiwode
26 May 23
4
Derrell Porter
26 May 23
4
Sandip Kapadia
26 May 23
4
Michael E. Kamarck
26 May 23
4
Saqib Islam
26 May 23
4
MAXINE GOWEN
26 May 23
4
Athena Countouriotis
26 May 23
4
Simona King
20 Apr 23
4
William Chou
5 Apr 23
4
Simona King
5 Apr 23
4
Mark S Forman
5 Apr 23
4
Edgar B. Cale
5 Apr 23
4
Alexandros Fotopoulos
5 Apr 23
SC 13G/A
Lynx1 Capital Management LP
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
4
Sandip Kapadia
2 Dec 22
4
Alexandros Fotopoulos
25 Nov 22
4
Monika Maria Toernsen
18 Nov 22